Background Renal transplantation, a cornerstone in modern medicine, offers a crucial solution for those grappling with end-stage renal diseases. However, organ transportation challenges necessitate innovative preservation methods. This study aims to enhance transplant viability by optimizing kidney preservation through advanced ultrasound technology. It continues previous work with our hemoglobin-based oxygen carrier (HBOC) compound, addressing oxygen deprivation during transport with the OxyVita organ storage device. Enhanced with sugars and amino acids, HBOC creates an extracellular storage solution that maintains high oxygen delivery and metabolism ex vivo, offering greater clinical value than current practices.

Methods Current market organ preservation solutions rely on dissolved oxygen, lacking active transport, which leads to ischemic necrosis and ROS build-up. Over 24-48 hours, control kidneys will be submerged in the University of Wisconsin (UW) solution, while study kidneys will be submerged and perfused with OxyVita. The NextGen LOGIQ e ultrasound system will be used to screen for healthy kidneys at removal and guide fine-needle biopsies every two hours. The Fine Needle Recognition Mode software allows for precise sectioning from the renal cortex, generating accurate data on tissue necrosis. Additionally, ultrasound-guided fluid collection will provide insights into critical metabolites. Post-experiment, periodic ultrasound assessments will monitor the transplanted kidney’s condition. The methodology incorporates color-flow Doppler and contrast-enhanced ultrasound for detailed structural and functional assessments, delineating perfusion patterns, detecting structural aberrations, and preserving renal echogenicity and corticomedullary differentiation, providing a reliable basis for clinical application.

Results Preliminary research shows OXYVITA optimizing its storage solution, currently aiming to reach a storage time between 24-48 hours. Preliminary studies conducted at the UWM School of Medicine in Olsztyn, Poland have evaluated the role of OxyVita as a component of an organ storage solution in the preservation of renal tissue. Results demonstrated that more than 20% greater preservation of renal structure using OxyVita solution compared to control solution.

Conclusion This study aims to confirm that the OxyVita solution deters pathophysiological processes. Data from renal tissue histology and spectrophotometry will be enhanced by high-quality imaging and contrast signals from the NextGen LOGIQ e system, strengthening the histopathological and biochemical findings. Leveraging advanced ultrasound technology, our investigation spans diverse dimensions, including assessing organ morphometrics, delineating architectural pathologies, understanding perfusion dynamics, and providing precise visualizations crucial for comprehensive research analyses to unravel rejection mechanisms within the application of the OxyVita product. Ultimately, our goal is to extend the shelf-life of kidneys to increase their transplantation viability for a broader patient population.